John E. Souness - Concepedia

Author

John E. Souness

Baker Engineering (United States)

Also Known As

JOHN E. SOUNESS, John E Souness, John E. Souness, John Souness

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Baker Engineering (United States)Barking and Dagenham College Essex Cardiothoracic Centre South College Abbott (United Kingdom)

About

John E. Souness is an author at Baker Engineering (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	20	788
2	Biochemistry	12	12	542
3	Natural Sciences	9	9	371
4	Cell Biology	3	3	183
5	Allergy	2	2	79

John E. Souness

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a ‘low‐affinity’ phosphodiesterase 4 conformer John E. Souness, Miriam Griffin, Christopher Maslen, British Journal of Pharmacology ImmunologyTnf AlphaInflammationMolecular PharmacologyTnfα Generation	1996	115
Anti‐inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor David Raeburn, Stephen L. Underwood, S.A. Lewis, British Journal of Pharmacology	1994	109
Characterization of guinea-pig eosinophil phosphodiesterase activity John E. Souness, Caroline M. Carter, Baljeet K. Diocee, Biochemical Pharmacology PhysiologyEosinophilic DisorderCellular BiochemistryProtein Phosphorylation	1991	105
Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY‐5445, vinpocetine and 1‐methyl‐3‐isobutyl‐8‐(methylamino)xanthine John E. Souness, R Brazdil, Baljeet K. Diocee, British Journal of Pharmacology	1989	80
The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy Iain M. McLay, Frank Halley, John E. Souness, Bioorganic & Medicinal Chemistry Rheumatoid DisorderRheumatologyAnti-inflammatoryMedicineOsteoarthritis	2001	78
Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors John E. Souness, Giles A. Hassall, David P. Parrott Biochemical Pharmacology BiochemistryMedicineVascular PharmacologyVascular BiologyAntisense Therapy	1992	77
An Algorithm-Directed Two-Component Library Synthesized Via Solid-Phase Methodology Yielding Potent and Orally Bioavailable p38 MAP Kinase Inhibitors Jeffrey M. McKenna, Frank Halley, John E. Souness, Journal of Medicinal Chemistry Combinatorial ChemistryMedicinal ChemistryDrug TargetBioorganic ChemistryPermeability Assays	2002	73
The effect of cyclic AMP and cyclic GMP phosphodiesterase inhibitors on the superoxide burst of guinea‐pig peritoneal macrophages Nicholas C. Turner, Lorna Wood, Fiona Burns, British Journal of Pharmacology Lung InflammationPharmacotherapyExperimental PharmacologyCyclic Amp PdeOxidative Stress	1993	62
Possible role of cyclic AMP phosphodiesterases in the actions of ibudilast on eosinophil thromboxane generation and airways smooth muscle tone John E. Souness, Maria Elena Villamil, Lisa C. Scott, British Journal of Pharmacology AsthmaPde IsoenzymesPde IvEosinophilic DisorderExperimental Pharmacology	1994	53
Mapping the kinase domain of janus kinase 3 Christopher Adams, David Aldous, Shelley Amendola, Bioorganic & Medicinal Chemistry Letters Signal TransductionMolecular PhysiologySignaling PathwayReceptor Tyrosine KinaseJanus Kinase 3	2003	50

Page 1